JP2002527481A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527481A5
JP2002527481A5 JP2000576854A JP2000576854A JP2002527481A5 JP 2002527481 A5 JP2002527481 A5 JP 2002527481A5 JP 2000576854 A JP2000576854 A JP 2000576854A JP 2000576854 A JP2000576854 A JP 2000576854A JP 2002527481 A5 JP2002527481 A5 JP 2002527481A5
Authority
JP
Japan
Prior art keywords
medicament according
medicament
androstene
dione
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000576854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527481A (ja
Filing date
Publication date
Priority claimed from US09/174,235 external-priority patent/US6153606A/en
Application filed filed Critical
Publication of JP2002527481A publication Critical patent/JP2002527481A/ja
Publication of JP2002527481A5 publication Critical patent/JP2002527481A5/ja
Pending legal-status Critical Current

Links

JP2000576854A 1998-10-16 1999-10-13 哺乳動物の記憶を改善する方法 Pending JP2002527481A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/174,235 US6153606A (en) 1998-10-16 1998-10-16 Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
US09/174,235 1998-10-16
PCT/US1999/024076 WO2000023080A1 (en) 1998-10-16 1999-10-13 IMPROVING MEMORY BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE AND 3β ESTERS THEREOF

Publications (2)

Publication Number Publication Date
JP2002527481A JP2002527481A (ja) 2002-08-27
JP2002527481A5 true JP2002527481A5 (enExample) 2007-01-25

Family

ID=22635389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000576854A Pending JP2002527481A (ja) 1998-10-16 1999-10-13 哺乳動物の記憶を改善する方法

Country Status (7)

Country Link
US (2) US6153606A (enExample)
EP (1) EP1123100B1 (enExample)
JP (1) JP2002527481A (enExample)
AT (1) ATE289819T1 (enExample)
CA (1) CA2344677A1 (enExample)
DE (1) DE69923988T2 (enExample)
WO (1) WO2000023080A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153606A (en) * 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
US6399085B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US6399084B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method for diminishing wrinkles and fine lines of the skin by the topical application of Δ5-androstene-3β-ol-7, 17 dione and metabolizable precursors thereof
US6465446B1 (en) 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US8084446B2 (en) * 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
ATE487488T1 (de) 2006-03-09 2010-11-15 Cambridge Entpr Ltd Neuartige antibiotische zusammensetzungen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5641766A (en) * 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
ATE227992T1 (de) * 1990-08-29 2002-12-15 Humanetics Corp Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
US5807848A (en) * 1990-08-29 1998-09-15 Humanetics Corporation Use of dehydroepeiandrosterone-3-carboxylates to control body weight
US5707983A (en) * 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
CA2148373A1 (en) * 1993-09-02 1995-03-09 Henry A. Lardy Delta 5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5420028A (en) * 1993-10-13 1995-05-30 Northeastern Ohio Universities Truncated human cholesterol 7α-hydroxylase, method of production and use thereof
GB9421093D0 (en) * 1994-10-19 1994-12-07 Univ Edinburgh Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
CA2250874A1 (en) * 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
US6153606A (en) * 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof

Similar Documents

Publication Publication Date Title
AU6634400A (en) Dose of an angiogenic factor and method of administering to improve myocardial blood flow
MX249762B (es) Acidos aldonicos de oligosacarido y su uso topico.
PT1410791E (pt) Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção
AU2003207016A1 (en) Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions
NO922004D0 (no) Oralt preparat for behandling av inflammatoriske tarmsykdommer
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
JP2007512371A5 (enExample)
JP2002527481A5 (enExample)
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
ATE241363T1 (de) Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
CA2271162A1 (en) Stearidonic acid compositions and uses thereof
NZ522242A (en) Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
EE200300155A (et) Antiprogestiinide kasutamine hormoonsõltuvate haiguste profülaktikaks ja raviks
NO20023102D0 (no) Metode og formulering for å behandle motstand mot antihypertensiver og lignende tilstander
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
DK1227814T3 (da) Hormonal sammensætning baseret på nomegestrolacetat og et östrogen samt anvendelse heraf
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
WO2000018353A3 (en) A novel inhibitor of cataract formation
WO2001085188A3 (en) Use of echinacea as a hematinic agent
DE69923988D1 (de) Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta-estern desselben
AU2001230543A1 (en) Physiologically active compositions based upon active ingredients of basidiomycotina and araliaceae
JP2003522795A5 (enExample)
JP2003522737A5 (enExample)
WO2003043579A3 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions